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Abstract
Purpose—For patients with a high likelihood of having metastatic disease (high-risk prostate 
cancer), bone scan is the standard, guideline-recommended test to look for bony metastasis. We 
quantified the use of bone scans and downstream procedures, along with associated costs, in 
patients with high-risk prostate cancer, and their use in low- and intermediate-risk patients for 
whom these tests are not recommended.
Methods and Materials—Patients in the Surveillance, Epidemiology, and End Results (SEER)-
Medicare database diagnosed with prostate cancer from 2004 to 2007 were included. Prostate 
specific antigen (PSA), Gleason score, and clinical T stage were used to define D’Amico risk 
categories. We report use of bone scans from the date of diagnosis to the earlier of treatment or 6 
months. In patients who underwent bone scans, we report use of bone-specific x-ray, computed 
tomography (CT), and magnetic resonance imaging (MRI) scans, and bone biopsy within 3 
months after bone scan. Costs were estimated using 2012 Medicare reimbursement rates.
Results—In all, 31% and 48% of patients with apparent low- and intermediate-risk prostate 
cancer underwent a bone scan; of these patients, 21% underwent subsequent x-rays, 7% CT, and 
3% MRI scans. Bone biopsies were uncommon. Overall, <1% of low- and intermediate-risk 
patients were found to have metastatic disease. The annual estimated Medicare cost for bone scans 
and downstream procedures was $11,300,000 for low- and intermediate-risk patients. For patients 
with apparent high-risk disease, only 62% received a bone scan, of whom 14% were found to have 
metastasis.
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Conclusions—There is overuse of bone scans in patients with low- and intermediate-risk 
prostate cancers, which is unlikely to yield clinically actionable information and results in a 
potential Medicare waste. However, there is underuse of bone scans in high-risk patients for whom 
metastasis is likely.
Introduction
More than 238,000 men will be diagnosed with prostate cancer in 2013 (1). Management of 
this common disease is very costly to the US health care system. A recent study showed that 
adoption of new technologies in prostate cancer management increased the annual cost of 
care in the US by $350 million (2). These figures for prostate cancer highlight the 
importance for research to examine health care use in this disease for potential opportunities 
in savings without compromising patient care.
Patients with newly diagnosed prostate cancer are stratified into low-, intermediate-, and 
high-risk groups based on clinical stage, prostate specific antigen (PSA) levels, and Gleason 
score. This stratification (staging) system serves not only to guide treatment decisions but 
also to help determine the extent of workup required. For patients with high-risk prostate 
cancer, a bone scan is the guideline-recommended imaging study to look for bony 
metastasis. On the other hand, for patients with low- and intermediate-risk disease, 
guidelines do not recommend the routine use of bone scans because metastatic disease is 
unlikely in these relatively indolent types of prostate cancer (3). These unnecessary scans are 
costly to the health care system, give unnecessary radiation dose to the patients, and can also 
lead to downstream consequences in terms of additional procedures to further work up 
“findings” from the bone scans.
Therefore, the goal of this study was to examine the prevalence of bone scan use in patients 
with low-, intermediate-, and high-risk prostate cancers; to quantify the use of additional 
imaging (such as dedicated, bone-specific computed tomography [CT] and magnetic 
resonance imaging [MRI] scans and x-rays [XR], as well as biopsies after bone scans); and 
to quantify costs to Medicare associated with the bone scans and these downstream 
procedures. We further quantify the proportion of patients with apparent low-, intermediate-, 
and high-risk cancers who are ultimately diagnosed with metastatic disease to determine 
whether these procedures led to clinically useful information.
Methods and Materials
Data source
We used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked 
database. This is a commonly used, population-based data source to examine patterns of care 
in older cancer patients. SEER is a National Cancer Institute-supported collection of cancer 
registries that covers approximately 28% of the US population (4). SEER provides details 
regarding age, race/ethnicity, marital status, census tract measure of education (a proxy for 
socioeconomic status), population density of patient residence, and geographic region. 
Medicare is the primary health insurance program for Americans 65 years and older; its 
claims data provide information regarding procedures and treatments that patients receive. 
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Medicare data from 12 months before prostate cancer diagnosis were used to calculate a 
validated comorbidity score specific for claims data (5). This study was exempted by the 
University of North Carolina at Chapel Hill Institutional Review Board.
Patient selection
Men diagnosed with prostate cancer between 2004 and 2007 were included. Patients were 
excluded if they were diagnosed with cancer at autopsy, if they had prior cancers, if the 
month and year of diagnosis were unknown, or if unknown diagnostic information precluded 
risk group stratification (including all patients diagnosed before 2004). To ensure that all 
claims related to initial diagnosis and management were available for analysis, we included 
only patients who had continuous Medicare Part A and B coverage with no enrollment in a 
health maintenance organization (HMO) for 12 months after diagnosis. These criteria 
resulted in 47,224 patients in the analytic cohort.
Risk group stratification
Patients were stratified into risk groups using standard criteria defined by D’Amico et al: 
low risk (clinical stage T1-T2a, Gleason score ≤6, and PSA ≤10 ng/mL), intermediate risk 
(T2b, or Gleason score 7, or PSA >10 ng/mL and ≤20 ng/mL), and high risk (T2c or T3a, or 
PSA >20 ng/mL, or Gleason score ≥8) (6). We grouped patients into “apparent” risk groups 
based on these criteria, which represents the information that was available at the time of the 
initial diagnosis and that was used for clinical decision making about whether to pursue a 
staging bone scan to look for metastasis. As one of the outcomes in this study, we examined 
the proportion of patients in each of these apparent risk groups who was diagnosed with 
metastatic (M1) disease.
Bone scan and imaging studies
The Current Procedural Technology/Healthcare Common Procedure Coding System (CPT/
HCPCS) codes in Medicare data provided information regarding imaging, procedures, and 
treatments. Bone scans performed after date of diagnosis and before the earlier of 180 days 
or date of first treatment were considered part of the initial staging workup. Because SEER 
provides only the month and year of diagnosis, we assigned each patient’s diagnosis to the 
first of each month and deemed this reasonable because bone scans are unlikely to be used 
for purposes other than cancer staging.
For patients who received a bone scan, we then examined uses of additional imaging and 
procedures: x-ray, CT, and MRI specific to bone evaluation, and bone biopsy. We defined 
imaging and procedures performed within 90 days after bone scan and before treatment as 
potential downstream studies to further work-up abnormalities identified on bone scan. A 
complete list of HCPCS codes is shown in the Appendix.
Statistical and cost analysis
We report the proportions of patients in each risk group who received a bone scan and 
subsequently underwent imaging and procedures. We further explore regional variation in 
use, as well as variation by primary treatment modality (conservative management, external 
beam radiation, non-external beam treatment). The reason for the latter is that external beam 
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radiation often includes a CT and/or MRI scan for treatment planning, which can be a source 
of confounding in this analysis for these 2 specific categories of imaging. Multivariate 
logistic regression models assessed for covariates associated with bone scan use in each risk 
group. All analysis was performed with SAS 9.2 (Cary, NC), and a P value of <.05 was 
considered statistically significant.
Direct cost to Medicare was calculated based on the cost of a bone scan from the CPT code 
78306, which accounted for the majority of Medicare’s bone scan claims among patients 
with prostate cancer. The 2012 Medicare national average reimbursement rate of $257.66 
was multiplied by the estimated annual incidence of prostate cancer in patients older than 
65. This figure was then multiplied by the proportion of patients receiving bone scans as 
reported in this study. Similarly, the costs of downstream imaging and procedures were 
estimated using 2012 national reimbursement rates multiplied by the relative frequency of 
each procedure.
Results
Baseline cohort characteristics are shown in Table 1. Overall, 83% of patients were of white 
ethnicity, and 42% had apparent high-risk cancer at diagnosis.
Table 2 and Figure 1 show the frequency of bone scans during initial workup in each 
apparent risk group, and the proportion within each group with diagnosed metastatic disease. 
Although metastatic disease is rare (<1% overall) in patients with apparent low- and 
intermediate-risk disease, 31% and 48% of patients in these groups underwent bone scans, 
respectively. Among high-risk patients, 62% received a bone scan and 12% overall had 
metastatic disease. There was regional variation in the use of bone scans in low- and 
intermediate-risk patients, with the highest use in the Northeast and lowest in the West. For 
high-risk cancer, regional variation in bone scan use was less dramatic.
Among patients who received a bone scan, the proportion who underwent additional scans 
within 90 days after the bone scan and before start of treatment is shown in Table 3. These 
data are stratified by risk group, first treatment, and SEER region. Overall, 20.7% of patients 
who received a bone scan received downstream bone-specific x-rays (22.2% low-risk, 19.9% 
intermediate-risk, and 20.7% high-risk); 7.8% received bone-specific CT scans (7.1%, 6.9%, 
and 8.6%), and 3.3% bone-specific MRIs (3.2%, 2.9%, and 3.6%). There was no statistically 
significant increase in CT or MRI use in external beam radiation versus that in other 
patients. The use of bone biopsies after bone scan was rare: only 76 patients (0.3%) 
underwent this procedure.
In multivariate analysis, Northeast region and higher comorbidity score were associated with 
increased bone scan use in all risk groups (Table 4). For low- and intermediate-risk patients, 
year of diagnosis was not associated with bone scan; for high-risk patients, later years were 
associated with increased bone scan use. Increasing age was associated with increased bone 
scan use for intermediate-risk patients. Further analysis demonstrated that older patients 
were more likely to have Gleason 4+3 disease: ages 66 to 69 (21.1%), ages 70 to 74 
(24.7%), ages 75 to 79 (26.0%), and ages 80 to 84 (27.5%, P<.001). This difference in 
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Gleason 4+3 disease by age may explain the increased use of bone scans in older patients 
with intermediate-risk prostate cancer.
The annual estimated cost to Medicare of bone scans for all patients is $19,300,000, 
including $9,300,000 for low- and intermediate-risk patients. An additional $2,000,000 is 
spent annually on downstream imaging after bone scan for low- and intermediate-risk 
patients (Fig. 2).
Discussion
In this analysis of SEER-Medicare data, we found that almost one-third of low-risk and 
almost one-half of intermediate-risk prostate cancer patients received a staging bone scan. 
Among these patients who had a bone scan, 21%, 7%, and 3% received further scans 
including bone-specific x-rays, CT, and MRI scans, respectively. We found that these 
patients had almost no chance of having metastatic disease—indicating that metastatic work-
up for patients with apparent low- and intermediate-risk cancer, which leads to $11.3 million 
in annual Medicare costs, is unlikely to yield useful clinical information. On the other hand, 
bone scan use was only 62% in patients with apparent high-risk prostate cancer, for whom 
staging studies are recommended by published guidelines (3). Among high-risk patients who 
received a bone scan, 14% were diagnosed with metastatic disease.
Early-stage prostate cancer has recently come under increased scrutiny, with an awareness of 
the overtreatment in patients with indolent disease and a pervasive use of new and expensive 
treatments with unproven clinical benefit (2). A recent study estimated that the use of new 
technologies in prostate cancer was associated with a $350 million increase in health care 
costs in 2005 alone (2). Although recent studies have focused on treatments, the total annual 
cost of imaging performed as part of staging workup is unknown. It is important for 
physicians to be judicious when ordering tests and procedures to spare patients from 
unnecessary procedures and to help curb rising health care costs. One way to accomplish 
this is to consider the test characteristics of imaging studies when deciding whether or not to 
perform a scan. Because patients with apparent low- and intermediate-risk prostate cancer 
almost never have metastatic disease at the time of diagnosis, the positive predictive value of 
a bone scan is low, and the risk of false-positive results is high. However, as we show in this 
study, bone scans are commonly performed in these patients, and these are frequently 
followed by additional bone imaging studies.
Three recent studies also using the SEER-Medicare dataset have examined the rate of bone 
scan use in prostate cancer (7–9). The most important difference between the prior studies 
and ours is that we examined rates of imaging by “apparent” risk group, which includes the 
following information available at the time of diagnosis: PSA, Gleason score (from 
diagnostic prostate biopsy), and clinical stage (rectal examination). Patients and physicians 
base their decisions on whether to obtain a bone scan from this information. In contrast, 
prior studies excluded men with metastatic disease, that is, a positive result of the bone scan, 
which may have led to biased results (7, 8). We have used a more recent cohort of patients 
than prior studies, and our examination of downstream imaging and procedures after bone 
scan is also unique. We believe that the $11.3 million annual Medicare cost from bone scans 
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and downstream tests for patients with low- and intermediate-risk prostate cancer represents 
a “waste” because the risk of these patients having metastatic disease is close to zero. Future 
studies should examine the potential overuse of staging scans in patients less than 65 years 
of age, and associated costs to private insurers, to fully assess the overall impact of this 
practice on health care expenditures.
On the other hand, our study also demonstrates an underuse of bone scans in high-risk 
prostate cancer patients, for whom this scan is recommended by published guidelines (3). As 
this study shows, among patients who had an apparent high-risk cancer and received a bone 
scan, 14% were found to have metastatic disease. Patients who did not have a bone scan may 
harbor metastatic disease but may pursue aggressive surgical or radiation treatment for an 
incurable cancer. This can lead not only to patient harm from unnecessary treatment but also 
to significant health care costs. We are currently undertaking a follow-up study of patient 
treatments and outcomes in this group of patients.
There are several potential limitations to this study. The SEER-Medicare database does not 
include individuals younger than 65 years. However, as the median age of diagnosis for 
prostate cancer is 67 years, this disease and its associated costs are highly relevant to 
Medicare. Although we attempted to examine x-rays, CT scans, and MRI scans specific to 
the assessment of bones, it is possible that some scans included may have been performed 
for another purpose. We limited the time window for capturing these downstream scans 
(within 90 days of bone scans) in an attempt to minimize this concern. Our examination of 
downstream imaging by treatment did not yield higher rates for patients who received 
external beam radiation (which commonly involves a pelvic CT and/or MRI for treatment 
planning) versus other treatments, suggesting that our bone-specific imaging codes were 
unlikely to have been confounded by other types of CT and MRI scans.
Conclusions
In summary, one-third to one-half of patients with apparent low- and intermediate-risk 
prostate cancer received staging bone scans, which have almost no chance of finding 
metastatic disease. However, only 62% of patients with apparent high-risk disease received a 
bone scan. These results demonstrate a pervasive lack of adherence to guidelines, and a 
common overuse and underuse of this test in prostate cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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This SEER-Medicare study examines the use of bone scans and downstream tests during 
initial prostate cancer workup. One-third to one-half of apparent low- and intermediate-
risk prostate cancer patients received bone scans—a proportion of whom also received 
further downstream tests—despite almost 0% risk of metastatic disease, and resulting in 
an $11 million annual cost to Medicare. We also report underuse of bone scans in 
apparent high-risk patients, for whom metastatic disease is likely.
Falchook et al. Page 8














Percentage of patients in each apparent risk group who underwent bone scans or 
downstream imaging studies, and percentage with metastatic disease. *For illustration 
purposes, percentages of patients who underwent x-ray (XR), computed tomography (CT), 
and magnetic resonance imaging (MRI) after bone scan were normalized to the total number 
of patients in each risk group (denominator) rather than the total number of patients who 
underwent a bone scan.
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Annual cost to Medicare of bone scans and downstream imaging tests.
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Table 1
Characteristics of the analytic cohort (N=47,224)
n (%)
Age at diagnosis (y)
 66–69 12,697 26.9
 70–74 14,383 30.5
 75–79 10,874 23.0
 80–84 6141 13.0
 85+ 3129 6.6
Race
 Nonwhite 8074 17.1
 White 39,150 82.9
Marital Status
 Married 32,466 68.7
 Not married/unknown 14,758 31.3
NCI Comorbidity Index
 0 30,326 64.2
 >0 16,898 35.8
Year of diagnosis
 2004 12,015 25.4
 2005 11,364 24.1
 2006 12,011 25.4
 2007 11,834 25.1
% Non-high school graduate in census tract
 Quartile 1 (lowest) 12,179 25.8
 Quartile 2 11,861 25.1
 Quartile 3 11,773 24.9
 Quartile 4 (highest) 11,411 24.2
Median household income in census tract
 Quartile 1 (lowest) 11,591 24.5
 Quartile 2 11,755 24.9
 Quartile 3 11,817 25.0
 Quartile 4 (highest) 12,061 25.5
Geographic region
 Central 8824 18.7
 Northeast 10,317 21.8
 South 8628 18.3
 West 19,455 41.2
Population Density
 Not Urban/missing 7364 15.6
 Urban 39,860 84.4
Apparent risk group
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n (%)
 High 19,885 42.1
 Intermediate 16,235 34.4
 Low 11,104 23.5
Abbreviation: NCI = National Cancer Institute.
Geographic regions are as follows: Northeast (Connecticut, New Jersey), South (Atlanta, Rural Georgia, Kentucky, Louisiana), Central (Detroit, 
Iowa, Utah, New Mexico), and West (California, Seattle, Hawaii).
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Table 2
Frequency of bone scans and metastatic disease in men with prostate cancer, stratified by apparent risk group 
at initial diagnosis
Low risk Intermediate risk High risk
Total no. of patients 11,104 16,235 19,885
Patients who received a bone scan (%)
 Overall (all regions) 31 48 62
  Central 26 46 61
  Northeast 46 63 68
  South 31 48 59
  West 24 43 60
Patients with metastatic disease (among all patients in risk group), n (%) 14 (0.1) 113 (0.7) 2432 (12)
Patients with metastatic disease (among those who had a bone scan), n (%) 11 (0.3) 85 (1.1) 1736 (14)
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